C26.8 C18 K63.5
Conditions
Interventions
Group 1: The additional examination (gastroscopy) takes place on the same day as the colonoscopy. In addition to pure endoscopy with image documentation, both tissue samples from the stomach and blood
Sponsors
European Health and Digital Executive Agency (HADEA),
Eligibility
Sex/Gender
All
Age
50 Years to 74 Years
Inclusion criteria
Inclusion criteria: - Patients that undergo screening or surveillance colonoscopy for lower GI neoplasia. - Patients that present for colorectal cancer / polyp screening or surveillance will be checked for inclusion. - Written informed consent
Exclusion criteria
Exclusion criteria: - OGD at a high volume endoscopic centre within the past 3 years - Known gastric cancer - Genetic cancer syndromes - Prior gastrectomy or bariatric gastric surgery - Known gastric precancerous conditions (gastric atrophy, intestinal metaplasia, dysplasia) - Acute upper GI bleeding within the last 4 weeks - Coagulation defects or medication prohibiting biopsy sampling - Pregnancy, breast-feeding women - Inability to actively consent to study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence of gastric cancer or gastric precancerous conditions and lesions that require endoscopic surveillance or treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| · Key performance indicators for upper GI endoscopy (OGD) as compared to quality standards in colonoscopy · development of a cost effectiveness model of screening OGD in different settings · Preferred strategy to enter screening program · Reasons for non-participation in gastric cancer screening · endoscopist quality to detect other relevant gastric lesions, oesophageal and duodenal diseases and conditions as compared to quality standards in colonoscopy (ADR, withdrawal time, reporting) · development of a model of cost effectiveness of screening OGD in different countries · Specimen and data allocation of screened subjects for additional analysis and follow up analysis if later applicable · Endoscopic imaging and analysis of varying results of endoscopy and histology · Optimal population to include in potential screening program · Blood Pepsinogen levels in correlation with endoscopic findings | — |
Countries
France, Germany, Ireland, Lithuania, Netherlands, Portugal
Contacts
Public ContactJochen Weigt
Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie
Outcome results
None listed